샘플 요청 목록

 카트 문의
시장보고서
상품코드
1536210

세계의 NTRK 융합 유전자 양성 진행성 고형암 시장

NTRK Fusion Gene Positive Advanced Solid Tumors
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 270 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

NTRK 융합 유전자 양성 진행성 고형암 세계 시장 규모는 2030년까지 5억 2,770만 달러에 달할 것으로 전망

2023년 3억 9,620만 달러로 추정되는 NTRK 융합 유전자 양성 진행성 고형암 세계 시장은 2023년부터 2030년까지 연평균 4.2% 성장하여 2030년에는 5억 2,770만 달러에 달할 것으로 예상됩니다. 본 보고서에서 분석한 부문 중 하나인 진단 유형은 CAGR 4.9%를 기록하여 분석 기간이 끝날 때까지 3억 80만 달러에 도달할 것으로 예상됩니다. 치료제 유형의 성장률은 분석 기간 동안 CAGR 3.3%로 추정됩니다.

미국 시장은 1억 790만 달러로 추정, 중국은 CAGR 7.9%로 성장할 것으로 예상

미국의 NTRK 융합 유전자 양성 진행성 고형암 시장은 2023년 1억 790만 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 1억 1,360만 달러 규모에 도달할 것으로 예상되며, 분석 기간인 2023-2030년 동안 7.9%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 1.4%와 3.2%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 유럽에서는 독일이 2.3%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

세계 NTRK 융합 유전자 양성 진행성 고형암 시장 - 주요 동향 및 촉진요인 요약

NTRK 융합 유전자 양성 진행성 고형암은 신경 영양성 티로신 수용체 키나아제(NTRK) 유전자가 다른 유전자와 융합되어 발암성 융합 단백질의 발현으로 이어지는 특정 유전자 이상에 의해 정의되는 암 범주를 나타냅니다. 이러한 융합은 드물지만 폐암, 갑상선암, 육종 등 다양한 유형의 종양에서 발생합니다. 일반적으로 NTRK 유전자 융합이 존재하면 세포 분열과 생존을 촉진하는 TRK 신호전달이 지속적으로 활성화되어 종양의 성장과 진행 가능성이 높다는 것을 나타냅니다. 이러한 융합 유전자의 확인은 TRK 융합 단백질의 활성을 특이적으로 억제할 수 있는 표적 치료제의 사용을 위한 지침이 될 수 있기 때문에 매우 중요합니다. 고정밀 유전자 검사와 분자진단의 출현으로 NTRK 융합 유전자 양성 종양 환자를 보다 정확하게 식별할 수 있게 되어 환자 결과를 크게 개선할 수 있는 맞춤형 치료 접근이 용이해졌습니다.

NTRK 융합 유전자 양성 종양에 대한 표적 치료제의 개발은 정밀 종양학에서 중요한 이정표가 되었습니다. 랄로트렉티닙, 엔트렉티닙 등 TRK 억제제로 알려진 약물은 종양의 기원과 조직형에 관계없이 NTRK 유전자 융합 종양 치료에 높은 효능을 보이고 있습니다. 라로트렉티닙과 엔트렉티닙은 NTRK 유전자 융합 단백질의 키나아제 활성을 특이적으로 억제하여 종양의 성장을 막고 종양 크기를 감소시키는 작용을 하며, NTRK 유전자 융합이 확인된 고형암 치료제로 FDA 승인을 받았습니다. FDA의 승인을 받았으며, 이는 부위별 진단적 암 치료로의 전환을 보여줍니다. 이러한 발전은 암 치료에서 유전자 프로파일링이 점점 더 중요해지고 있으며, 신체 부위가 아닌 종양의 유전적 특징에 따라 보다 개인화되고 효과적인 치료 계획을 세울 수 있다는 점을 강조합니다. 현재 진행 중인 임상시험에서 이러한 TRK 억제제 및 새로운 TRK 억제제의 잠재력을 계속 탐구하고 있으며, 암 분야에서 표적 치료의 이해와 적용이 확대되고 있습니다.

NTRK 융합 유전자 양성 진행성 고형암 표적 치료제 시장의 성장은 유전자 스크리닝 기술의 발전, 암 분야에서 개인 맞춤형 의료에 대한 인식 증가, 여러 종양 유형에 대한 TRK 억제제의 광범위한 효능 등 여러 요인에 의해 주도되고 있습니다. 향상된 유전자 검사 기능을 통해 NTRK 억제제의 혜택을 받을 수 있는 환자를 보다 정확하게 식별할 수 있어 치료 결과와 자원 배분을 최적화할 수 있습니다. 또한, 정밀의료에 대한 의료계의 관심이 높아지면서 표적치료제 도입이 촉진되고, 종양학 유전자 연구에 대한 정책 전환과 자금 지원 확대가 이뤄지고 있습니다. 암 치료가 더욱 개인화됨에 따라 소비자 행동에도 큰 변화가 일어나고 있으며, 환자들은 더 나은 효과와 부작용 감소를 약속하는 유전체 검사 및 개인화된 치료 계획을 점점 더 많이 요구하고 있습니다. 또한, TRK 억제제의 성공적인 임상 결과는 내성 메커니즘을 극복하거나 환자의 내성을 개선할 수 있는 차세대 TRK 억제제 개발에 대한 지속적인 투자와 연구를 촉진하고 있습니다. 이러한 추세는 암 치료제 시장에서 틈새 시장이지만 매우 중요한 분야인 TRK 억제제의 확장을 촉진하고 있으며, 보다 표적화되고 효과적인 암 치료 전략에 대한 종합적인 움직임을 반영하고 있습니다.

조사 대상 기업 예시(주목받는 86개 기업)

  • Amoy Diagnostics Co.
  • AnHeart Therapeutics
  • ARUP Laboratories
  • Bayer AG
  • CD Genomics
  • Chugai Pharmaceutical Co.
  • Empire Genomics LLC
  • EntroGen, Inc.
  • F. Hoffmann-La Roche AG
  • GenPath
  • Illumina, Inc.
  • LGC Standards
  • NeoGenomics Laboratories, Inc.
  • OncoDNA SA
  • Thermo Fisher Scientific, Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 24.09.05

Global NTRK Fusion Gene Positive Advanced Solid Tumors Market to Reach US$527.7 Million by 2030

The global market for NTRK Fusion Gene Positive Advanced Solid Tumors estimated at US$396.2 Million in the year 2023, is expected to reach US$527.7 Million by 2030, growing at a CAGR of 4.2% over the analysis period 2023-2030. Diagnostics Type, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$300.8 Million by the end of the analysis period. Growth in the Therapeutics Type segment is estimated at 3.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$107.9 Million While China is Forecast to Grow at 7.9% CAGR

The NTRK Fusion Gene Positive Advanced Solid Tumors market in the U.S. is estimated at US$107.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$113.6 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global NTRK Fusion Gene Positive Advanced Solid Tumors Market - Key Trends and Drivers Summarized

NTRK fusion gene positive advanced solid tumors represent a category of cancer defined by specific genetic anomalies where neurotrophic tyrosine receptor kinase (NTRK) genes are fused with other genes, leading to the expression of oncogenic fusion proteins. These fusions are rare but occur across a variety of tumor types, including lung cancer, thyroid cancer, sarcoma, and others. The presence of NTRK gene fusions generally indicates a high likelihood of tumor growth and progression due to the continuous activation of TRK signaling, which promotes cell division and survival. Identification of these fusions is critical as it guides the use of targeted therapies that can specifically inhibit the activity of TRK fusion proteins. The advent of high-precision genetic testing and molecular diagnostics has enabled more accurate identification of patients with NTRK fusion-positive tumors, facilitating tailored treatment approaches that significantly improve patient outcomes.

The development of targeted therapies for NTRK fusion gene positive tumors has been a significant milestone in precision oncology. Drugs known as TRK inhibitors, such as larotrectinib and entrectinib, have shown high efficacy in treating tumors with NTRK gene fusions, regardless of the tumor’s origin or histology. These therapies work by specifically blocking the kinase activity of the TRK fusion proteins, thereby halting tumor growth and reducing tumor size. Both larotrectinib and entrectinib have received FDA approval for the treatment of any solid tumor with a confirmed NTRK gene fusion, marking a shift towards site-agnostic cancer treatment. This development highlights the growing importance of genetic profiling in cancer therapy, enabling more personalized, effective treatment plans based on the genetic characteristics of a tumor rather than its location in the body. Ongoing clinical trials continue to explore the potential of these and newer TRK inhibitors, expanding our understanding and application of targeted treatments in oncology.

The growth in the market for treatments targeting NTRK fusion gene positive advanced solid tumors is driven by several factors, including advancements in genetic screening technologies, increased awareness of personalized medicine in oncology, and the broad efficacy of TRK inhibitors across multiple tumor types. Enhanced genetic testing capabilities allow for more precise identification of patients who can benefit from NTRK inhibitors, thus optimizing treatment outcomes and resource allocation. Furthermore, the healthcare sector's growing emphasis on precision medicine has encouraged the adoption of targeted therapies, supported by policy shifts and increased funding for genetic research in oncology. As cancer treatments become more personalized, there is also a significant shift in consumer behavior, with patients increasingly seeking out genomic testing and personalized treatment plans that promise better efficacy and fewer side effects. Additionally, the successful clinical outcomes associated with TRK inhibitors have spurred ongoing investment and research, leading to the development of next-generation TRK inhibitors that may overcome resistance mechanisms or improve patient tolerance. These trends collectively drive the expansion of this niche yet crucial segment of the cancer therapeutics market, reflecting an overarching move towards more targeted, effective cancer care strategies.

Select Competitors (Total 86 Featured) -

  • Amoy Diagnostics Co., Ltd.
  • AnHeart Therapeutics
  • ARUP Laboratories
  • Bayer AG
  • CD Genomics
  • Chugai Pharmaceutical Co., Ltd.
  • Empire Genomics LLC
  • EntroGen, Inc.
  • F. Hoffmann-La Roche AG
  • GenPath
  • Illumina, Inc.
  • LGC Standards
  • NeoGenomics Laboratories, Inc.
  • OncoDNA SA
  • Thermo Fisher Scientific, Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • NTRK Fusion Gene Positive Advanced Solid Tumors - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of NTRK Fusion Gene Positive Tumors Throws the Spotlight On Targeted Therapies
    • Advances in Genetic Testing Drive Adoption of Personalized Cancer Treatments
    • Rising Global Cancer Incidence Strengthens the Business Case for NTRK-Targeted Therapies
    • Insurance Coverage and Reimbursement Policies for Genetic Testing Drive Market Acceptance
    • Regulatory Fast-Tracking of Promising Oncology Drugs Accelerates Time to Market
    • Integration of NTRK Testing in Routine Cancer Diagnostics Throws the Spotlight On Early Detection
    • Growing Demand for Non-Chemotherapy Cancer Treatments Generates Opportunities for NTRK Inhibitors
    • Emerging Data on Long-Term Efficacy and Safety of NTRK Inhibitors Sustain Market Confidence
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World NTRK Fusion Gene Positive Advanced Solid Tumors Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Diagnostics Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Diagnostics Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Diagnostics Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Therapeutics Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Therapeutics Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Therapeutics Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cancer Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Cancer Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Cancer Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Cancer Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Cancer Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Cancer Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • JAPAN
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • CHINA
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • EUROPE
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • FRANCE
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • GERMANY
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • INDIA
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • AFRICA
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제